RT期刊文章SR电子T1肺部内膜切除术后的持续运动不耐受性，用于CTEPH JF欧洲呼吸杂志JO EUR RESSIR J FD欧洲呼吸学会SP 2000109 DO 10.1183/13993003.003.003.00109-2020 A1 RUIGROK，RUIGROK，RUIGROK，RUIGROK，RUIGR188bet官网地址OK，dieuwertje a1 meiijboom，lililian，Lilian J. A. Asenent J.A1 Boonstra，Anco A1 Braams，Natalia J. A1 Van Wezenbeek，Jessie A1 De Man，Frances S. A1 Marcus，J。TimA1 Vonk Noordegraaf，Anton A1 Symersky，Petr A1 Bogaard，Harm-Jan Yr 2020 UL HTTP：// 2020 UL HTTP：//www.qdcxjkg.com/content/early/2020/03/12/12/13993003.00109-2020.ABSTRACT ABSTRACT AB ABS AM AIM血液动力学标准化是慢性血栓栓塞肺部肺部高血压（CTEPH）的肺部内部切除术（PEA）的最终目标。然而，血液动力学的归一化是否转化为运动能力的归一化。豌豆后运动不耐受的发生率，决定因素和临床意义是未知的。我们进行了前瞻性分析，以确定豌豆后运动不耐受的发生率，评估运动能力和（静止）血液动力学之间的关系，并寻找豌豆后运动不耐受的术前预测指标。根据临床方案，所有患者都接受了心肺运动测试（所有患者）CPET），右心导管插入术（RHC）和心脏磁共振（CMR）成像之前和豌豆后6个月。运动不耐受定义为预测的峰值Vo2 <80％。CPET参数被判断为确定运动限制的原因。在运动不耐受和静止的血液动力学和CMR衍生的右心（RV）功能之间分析了关系。使用逻辑回归分析分析了运动不耐受的潜在术前预测指标。68例患者被包括在最终分析中。 45 patients (66%) had exercise intolerance 6 months after PEA; in 20 patients this was primarily caused by a cardiovascular limitation. The incidence of residual PH was significantly higher in patients with persistent exercise intolerance (p 0.001). However, 27 out of 45 patients with persistent exercise intolerance had no residual PH. In the multivariate analysis, preoperative transfer factor for carbon monoxide (TLCO) was the only predictor of exercise intolerance after PEA.Conclusions The majority of CTEPH patients has exercise intolerance after PEA, often despite normalisation of resting hemodynamics. Not all exercise intolerance after PEA is explained by the presence of residual PH, and lower preoperative TLCO was a strong predictor of exercise intolerance 6 months after PEA.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ruigrok has nothing to disclose.Conflict of interest: Dr. Meijboom has nothing to disclose.Conflict of interest: Dr. Nossent has nothing to disclose.Conflict of interest: Dr. Boonstra has nothing to disclose.Conflict of interest: Dr. Braams has nothing to disclose.Conflict of interest: Dr. van Wezenbeek has nothing to disclose.Conflict of interest: Dr. de Man has nothing to disclose.Conflict of interest: Dr. Marcus has nothing to disclose.Conflict of interest: Dr. Vonk Noordegraaf reports grants from Actelion, grants from GSK, grants from Pfizer, grants from Bayer, outside the submitted work.Conflict of interest: Dr. Symersky has nothing to disclose.Conflict of interest: Dr. Bogaard reports grants from Actelion, grants from GSK, grants from Pfizer, grants from Bayer, grants from Therabel, outside the submitted work.